Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 12

1.

Determination of melphalan in human plasma by UPLC-UV method.

Huang L, Cheah V, Chan D, Marzan F, Dvorak CC, Aweeka FT, Long-Boyle J.

Cancer Chemother Pharmacol. 2019 May;83(5):905-910. doi: 10.1007/s00280-019-03786-6. Epub 2019 Feb 13.

PMID:
30847504
2.

Strong correlation of lumefantrine concentrations in capillary and venous plasma from malaria patients.

Huang L, Mwebaza N, Kajubi R, Marzan F, Forsman C, Parikh S, Aweeka FT.

PLoS One. 2018 Aug 16;13(8):e0202082. doi: 10.1371/journal.pone.0202082. eCollection 2018.

3.

Concomitant nevirapine impacts pharmacokinetic exposure to the antimalarial artemether-lumefantrine in African children.

Huang L, Carey V, Lindsey JC, Marzan F, Gingrich D, Graham B, Barlow-Mosha L, Ssemambo PK, Kamthunzi P, Nachman S, Parikh S, Aweeka FT; IMPAACT P1079 protocol team.

PLoS One. 2017 Oct 24;12(10):e0186589. doi: 10.1371/journal.pone.0186589. eCollection 2017.

4.

Parasite Clearance and Artemether Pharmacokinetics Parameters Over the Course of Artemether-Lumefantrine Treatment for Malaria in Human Immunodeficiency Virus (HIV)-Infected and HIV-Uninfected Ugandan Children.

Kajubi R, Huang L, Were M, Kiconco S, Li F, Marzan F, Gingrich D, Nyunt MM, Ssebuliba J, Mwebaza N, Aweeka FT, Parikh S.

Open Forum Infect Dis. 2016 Dec 15;3(4):ofw217. doi: 10.1093/ofid/ofw217. eCollection 2016 Oct.

5.

Phase I safety, pharmacokinetics, and pharmacogenetics study of the antituberculosis drug PA-824 with concomitant lopinavir-ritonavir, efavirenz, or rifampin.

Dooley KE, Luetkemeyer AF, Park JG, Allen R, Cramer Y, Murray S, Sutherland D, Aweeka F, Koletar SL, Marzan F, Bao J, Savic R, Haas DW; AIDS Clinical Trials Group A5306 Study Team.

Antimicrob Agents Chemother. 2014 Sep;58(9):5245-52. doi: 10.1128/AAC.03332-14. Epub 2014 Jun 23.

6.

Relationship between weight, efavirenz exposure, and virologic suppression in HIV-infected patients on rifampin-based tuberculosis treatment in the AIDS Clinical Trials Group A5221 STRIDE Study.

Luetkemeyer AF, Rosenkranz SL, Lu D, Marzan F, Ive P, Hogg E, Swindells S, Benson CA, Grinsztejn B, Sanne IM, Havlir DV, Aweeka F; Adult AIDS Clinical Trials Group A5221 Study Team.

Clin Infect Dis. 2013 Aug;57(4):586-93. doi: 10.1093/cid/cit246. Epub 2013 Apr 16.

7.

Model-based estimates of the effects of efavirenz on bedaquiline pharmacokinetics and suggested dose adjustments for patients coinfected with HIV and tuberculosis.

Svensson EM, Aweeka F, Park JG, Marzan F, Dooley KE, Karlsson MO.

Antimicrob Agents Chemother. 2013 Jun;57(6):2780-7. doi: 10.1128/AAC.00191-13. Epub 2013 Apr 9.

8.

Concomitant efavirenz reduces pharmacokinetic exposure to the antimalarial drug artemether-lumefantrine in healthy volunteers.

Huang L, Parikh S, Rosenthal PJ, Lizak P, Marzan F, Dorsey G, Havlir D, Aweeka FT.

J Acquir Immune Defic Syndr. 2012 Nov 1;61(3):310-6. doi: 10.1097/QAI.0b013e31826ebb5c.

9.
11.

Development and validation of a high-performance liquid chromatography/tandem mass spectrometry method for the determination of artemether and its active metabolite dihydroartemisinin in human plasma.

Huang L, Jayewardene AL, Li X, Marzan F, Lizak PS, Aweeka FT.

J Pharm Biomed Anal. 2009 Dec 5;50(5):959-65. doi: 10.1016/j.jpba.2009.06.051. Epub 2009 Jul 7.

12.

Development and validation of a hydrophilic interaction liquid chromatography-tandem mass spectrometry method for determination of isoniazid in human plasma.

Huang L, Marzan F, Jayewardene AL, Lizak PS, Li X, Aweeka FT.

J Chromatogr B Analyt Technol Biomed Life Sci. 2009 Jan 15;877(3):285-90. doi: 10.1016/j.jchromb.2008.12.024. Epub 2008 Dec 24.

Supplemental Content

Loading ...
Support Center